Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,644.80up ₹17.30 (1.06%)BSE ₹1,640.10
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,627.50.
28 Oct: open ₹1,625.00, high ₹1,650.00, low ₹1,609.10
52-week range of traded prices to 28 Oct 2026
₹1,081.40Low, 28 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹94,638 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.49
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.50
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,54,48548.5% delivered
Aurobindo Pharma board meetings
124 filed, newest first. Page 2 of 3.
Jan 2020
Nov 2019
12 Nov · Board meeting
Oct 2019
Aug 2019
7 Aug · Board meeting
Jul 2019
26 Jul · Board meeting
May 2019
28 May · Board meeting
18 May · Board meeting
Feb 2019
7 Feb · Board meeting
Jan 2019
Nov 2018
12 Nov · Board meeting
Oct 2018
Aug 2018
9 Aug · Board meeting
Jul 2018
May 2018
16 May · Board meeting
Jan 2018
Oct 2017
Jul 2017
May 2017
29 May · Board meeting
Jan 2017
Oct 2016
Aug 2016
May 2016
Jan 2016
Nov 2015
Oct 2015
Jul 2015
May 2015
Feb 2015
Jan 2015
20 Jan · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2014. Further, the Board will also consider 2nd interim Dividend, if any, for the financial year 2014-15.
Dec 2014
Nov 2014
25 Nov · Board meeting
Board of Directors of the Company at Meeting on November 25, 2014 has, inter alia, considered and approved raising of funds by the Company through Issue of Securities upto an amount of USD 350 Million or Rupee equivalent thereof through follow on offer, qualified institutions placement, further public offer and / or private placement or by such other method subject to approval of the shareholders. The Board has constituted a Securities Issue Committee consisting five Board Members including two Independent Directors, to do all such acts, deeds, matters and things as may be required for Issue of Securities as they may deem fit in accordance with the applicable laws.21 Nov · Board meeting
To inter alia consider raising of funds through issue of securities.
Oct 2014
20 Oct · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2014.
Jul 2014
21 Jul · Board meeting
To consider, inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2014.
May 2014
Jan 2014
22 Jan · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2013.
Oct 2013
22 Oct · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30,2013.
Sep 2013
12 Sep · Board meeting
Aug 2013
12 Aug · Board meeting
Jul 2013
29 Jul · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2013.
May 2013
17 May · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2013.Further, the Board will also consider recommendation of Final Dividend, if any, for the year 2012-13.
Jan 2013
21 Jan · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2012.
Oct 2012
23 Oct · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2012.
Jul 2012
23 Jul · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2012.
May 2012
30 May · Board meeting
9 May · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2012.
Feb 2012
10 Feb · Board meeting
Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on February 10, 2012 to consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2011. The Company has now informed the Exchange that aforesaid Board Meeting has been postponed due to unavoidable circumstances. The meeting is now scheduled to be held on February 13, 2012.
Jan 2012
30 Jan · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2011.